

**Chammas & Marcheteau advises advises Supernova Invest on
SeqOne Genomics' €20 million fundraising
(Software/AI/Biotechnology)**

Chammas & Marcheteau advised Supernova Invest, lead investor in the €20 million Series A fundraising round of SeqOne Genomics, alongside Mérieux Equity Partners, Elaia and Omnes.

Founded in 2017, SeqOne Genomics develops next-generation genomic analysis software based on artificial intelligence. The company supports more than 140 laboratories in 22 countries, with the aim of accelerating personalized diagnosis in oncology and rare diseases.

With this new funding, SeqOne Genomics aims to strengthen its international presence, particularly in the United States, and to pursue its external growth strategy, notably through targeted acquisitions.

The **Chammas & Marcheteau** team was composed of **Lola Chammas** (partner) and **Julien Delacroix** (associate) on corporate aspects, **Christophe Moreau** (partner) and **Franck Hallel** (associate) on tax aspects, and **Aude Spinasse** (partner) and **Constance Parini** (associate) on intellectual property aspects.

About Chammas & Marcheteau

Chammas & Marcheteau is a Paris-based independent law firm that advises companies, investment funds and entrepreneurs on their transactions and development strategies in France and abroad. With more than 60 specialists in business law, including 16 partners, the Firm offers its clients expertise in Private Equity, Mergers & Acquisitions, Funds and Financial Services, Corporate, Restructuring and Turnaround, Tax, Intellectual Property and Information Technology, Employment Law, Real Estate and Business Litigation.